Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $23

Benzinga · 09/27 17:16
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $25 to $23.